240 related articles for article (PubMed ID: 22507953)
1. Can we rely on PET in the follow-up of advanced seminoma patients?
Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
[TBL] [Abstract][Full Text] [Related]
2. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
3. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
[TBL] [Abstract][Full Text] [Related]
4. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
5. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
[TBL] [Abstract][Full Text] [Related]
7. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
8. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
9. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
[TBL] [Abstract][Full Text] [Related]
10. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
[TBL] [Abstract][Full Text] [Related]
11. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
12. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
13. False-positive finding in FDG-PET in a patient with seminoma and sarcoidosis.
Liepe K
Acta Clin Belg; 2015 Apr; 70(2):138-40. PubMed ID: 25409626
[TBL] [Abstract][Full Text] [Related]
14. Positive FDG-PET/CT scans of a residual seminoma after chemotherapy and radiotherapy: case report and review of the literature.
Bilen MA; Hariri H; Leon C; Guo CC; Kuban DA; Pisters LL; Tu SM
Clin Genitourin Cancer; 2014 Aug; 12(4):e147-50. PubMed ID: 24674785
[No Abstract] [Full Text] [Related]
15. A pitfall of 18-fluorodeoxyglucose-PET in a patient with a tattoo.
Nam H; Smith S; Laing R
Lancet Oncol; 2007 Dec; 8(12):1147-1148. PubMed ID: 18054884
[No Abstract] [Full Text] [Related]
16. The role of 18F-FDG PET/CT in the management of testicular cancers.
Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
[TBL] [Abstract][Full Text] [Related]
17. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
[TBL] [Abstract][Full Text] [Related]
18. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
Müller J; Schrader AJ; Jentzmik F; Schrader M
Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT impact on testicular tumours clinical management.
Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
